Ironwood Pharmaceuticals officially released its financial report for the fourth quarter and full year of 2025 today.

The company not only fully achieved the financial guidance targets set last year, but also reaffirmed its strong expectations for business development in 2026 based on solid data. In a complex and ever-changing market environment, this biopharmaceutical company, focused on innovative therapies for gastrointestinal diseases, has demonstrated outstanding operational resilience. The commercialization progress of its core product line and the strategic layout of its R&D pipeline have injected sustained momentum for future growth. Notably, the company's management emphasized in the financial report that all key performance indicators for 2025 met or exceeded expectations, laying a solid foundation for the strategic advancement in 2026. As global medical demand continues to evolve, Ironwood Pharmaceuticals is continuously consolidating its competitive advantage in the specialty treatment field through precise market positioning and efficient resource allocation.